1. Home
  2. IROH vs APLT Comparison

IROH vs APLT Comparison

Compare IROH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROH
  • APLT
  • Stock Information
  • Founded
  • IROH 2021
  • APLT 2016
  • Country
  • IROH United States
  • APLT United States
  • Employees
  • IROH N/A
  • APLT N/A
  • Industry
  • IROH
  • APLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROH
  • APLT Health Care
  • Exchange
  • IROH Nasdaq
  • APLT Nasdaq
  • Market Cap
  • IROH 91.2M
  • APLT 80.3M
  • IPO Year
  • IROH 2023
  • APLT 2019
  • Fundamental
  • Price
  • IROH $10.38
  • APLT $0.61
  • Analyst Decision
  • IROH
  • APLT Buy
  • Analyst Count
  • IROH 0
  • APLT 7
  • Target Price
  • IROH N/A
  • APLT $6.10
  • AVG Volume (30 Days)
  • IROH 44.0K
  • APLT 4.2M
  • Earning Date
  • IROH 01-01-0001
  • APLT 03-05-2025
  • Dividend Yield
  • IROH N/A
  • APLT N/A
  • EPS Growth
  • IROH N/A
  • APLT N/A
  • EPS
  • IROH 0.20
  • APLT N/A
  • Revenue
  • IROH N/A
  • APLT N/A
  • Revenue This Year
  • IROH N/A
  • APLT N/A
  • Revenue Next Year
  • IROH N/A
  • APLT $2,622.90
  • P/E Ratio
  • IROH $53.07
  • APLT N/A
  • Revenue Growth
  • IROH N/A
  • APLT N/A
  • 52 Week Low
  • IROH $9.97
  • APLT $0.54
  • 52 Week High
  • IROH $11.11
  • APLT $10.62
  • Technical
  • Relative Strength Index (RSI)
  • IROH N/A
  • APLT 27.17
  • Support Level
  • IROH N/A
  • APLT $0.54
  • Resistance Level
  • IROH N/A
  • APLT $0.66
  • Average True Range (ATR)
  • IROH 0.00
  • APLT 0.06
  • MACD
  • IROH 0.00
  • APLT 0.11
  • Stochastic Oscillator
  • IROH 0.00
  • APLT 40.99

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: